Skip to main content

textochbilcontainer

/about-moberg

Moberg Pharma – a different kind of pharma company

textochbilcontainer

/about-moberg/business-model

A business model with faster time to market and lower development risk compared with conventional drug development

textochbilcontainer

/about-moberg/innovation-engine

Each year, we evaluate in excess of 100 new business opportunities to identify future bestsellers

textochbilcontainer

/products/kerasalr-nailtm

We sell Kerasal Nail through 30,000 retail outlets in the U.S

Moberg Pharma is a rapidly growing Swedish pharmaceutical company commercializing proprietary, acquired and licensed products in the global market. Initially, the company specialized in the treatment of skin diseases, with a focus on treatments for nail fungus. On March 29, 2019, the company divested its OTC Business, see press release

Stockvalue 2013-05-20 14:00
32,90 kr
+2,5 %
Interview with CEO Peter Wolpert
Peter
Our global markets

Subscribe

Get our latest press releases and reports

 

Latest report

2019-04-16 Moberg Pharma Annual Report 2018

Calendar/presentations

Next calendar event: 2019-05-14 Interim report for January - March 2019

Increased sales

Mycological cure rate after MOB-015 treatment